U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07235202) titled 'A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy' on Nov. 14.
Brief Summary: This Phase Ib/IIa study is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of MR001 Combined with Chemotherapy in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) who have progressed after first-line therapy.
Study Start Date: Dec. 22
Study Type: INTERVENTIONAL
Condition:
Pancreatic Ductal Adenocarcinoma (PDAC)
Intervention:
DRUG: MR001
Intravenous infusion
DRUG: Irinotecan Li...